Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals

Cancer

Volumn 121, Issue 7, 2015, Pages 1088-1097

  Ladabaum, Uri ^a   Mannalithara, Ajitha ^a   Jandorf, Lina ^b   Itzkowitz, Steven H ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

adherence; colorectal cancer; colorectal neoplasia; disparities; screening

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SCREENING; CAUCASIAN; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH INSURANCE; HISPANIC; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; OCCULT BLOOD TEST; PATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; CANCER STAGING; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; FEMALE; FOLLOW UP; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE; PATIENT NAVIGATION; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84925444581     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29162     Document Type: Article

References (46)

1. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328: 1365-1371.
2. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000; 343: 1603-1607.
3. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013; 369: 1106-1114.
4. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996; 348: 1472-1477.
5. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O.; Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996; 348: 1467-1471.
6. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010; 375: 1624-1633.
7. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst. 2011; 103: 1310-1322.
8. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012; 366: 2345-2357.
9. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366: 687-696.
10. Pignone M, Saha S, Hoerger T, Mandelblatt J.; Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2002; 137: 96-104.
11. Lansdorp-Vogelaar I, Knudsen AB, Brenner H.; Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011; 33: 88-100.
12. Sharaf RN, Ladabaum U.; Comparative effectiveness and cost-effectiveness of screening colonoscopy vs sigmoidoscopy and alternative strategies. Am J Gastroenterol. 2013; 108: 120-132.
13. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 627-637.
14. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening test use-United States, 2012. MMWR Morb Mortal Wkly Rep. 2013; 62: 881-888.
15. Fenton JJ, Tancredi DJ, Green P, Franks P, Baldwin LM.; Persistent racial and ethnic disparities in up-to-date colorectal cancer testing in medicare enrollees. J Am Geriatr Soc. 2009; 57: 412-418.
16. Semrad TJ, Tancredi DJ, Baldwin LM, Green P, Fenton JJ.; Geographic variation of racial/ethnic disparities in colorectal cancer testing among medicare enrollees. Cancer. 2011; 117: 1755-1763.
17. Freeman HP.; The origin, evolution, and principles of patient navigation. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1614-1617.
18. Chen LA, Santos S, Jandorf L, et al. A program to enhance completion of screening colonoscopy among urban minorities. Clin Gastroenterol Hepatol. 2008; 6: 443-450.
19. Braschi CD, Sly JR, Singh S, Villagra C, Jandorf L.; Increasing colonoscopy screening for Latino Americans through a patient navigation model: a randomized clinical trial. J Immigr Minor Health. 2014; 16: 934-940.
20. Elkin EB, Shapiro E, Snow JG, Zauber AG, Krauskopf MS.; The economic impact of a patient navigator program to increase screening colonoscopy. Cancer. 2012; 118: 5982-5988.
21. Jandorf L, Braschi C, Ernstoff E, et al. Culturally targeted patient navigation for increasing African Americans' adherence to screening colonoscopy: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1577-1587.
22. Lebwohl B, Capiak K, Neugut AI, Kastrinos F.; Risk of colorectal adenomas and advanced neoplasia in Hispanic, black and white patients undergoing screening colonoscopy. Aliment Pharmacol Ther. 2012; 35: 1467-1473.
23. Lee KK, Jandorf L, Thelemaque L, Itzkowitz SH.; Colorectal neoplasia detection among black and Latino individuals undergoing screening colonoscopy: a prospective cohort study. Gastrointest Endosc. 2014; 79: 466-472.
24. Jandorf L, Stossel LM, Cooperman JL, et al. Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities. Cancer. 2013; 119: 612-620.
25. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012; 172: 575-582.
26. Ladabaum U, Song K.; Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology. 2005; 129: 1151-1162.
27. Pelto DJ, Sly JR, Winkel G, et al. Predicting colonoscopy completion among African Americans and Latinos participating in a patient navigation program. J Racial and Ethnic Health Disparities. In press. 2014.
28. Ladabaum U, Allen J, Wandell M, Ramsey S.; Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1567-1576.
29. Ladabaum U, Ferrandez A, Lanas A.; Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2765-2776.
30. Surveillance, Epidemiology, and End Results (SEER) Program SEER Stat Database: Incidence-SEER 13 Registries research data, November 2011 submission, vintage 2009 populations (1992-2009). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch [released April 2012, based on the November 2011 submission]. Available at: http://www.seer.cancer.go. Accessed March 26, 2014.[WorldCat]
31. Arias E.; United States life tables, 2008. Natl Vital Stat Rep. 2012; 61: 1-63.
32. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008; 134: 1570-1595.
33. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR.; Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012; 143: 844-857.
34. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366: 697-706.
35. Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C.; High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol. 2012; 10: 633-638.
36. van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013; 62: 409-415.
37. Centers for Medicare and Medicaid Services. Physician Fee Schedule 2012. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/. Accessed March 4, 2014.[WorldCat]
38. Centers for Medicare and Medicaid Services. Inpatient Prospective Payment System 2012. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/. Accessed March 4, 2014.[WorldCat]
39. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule 2010. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/. Accessed March 4, 2014.[WorldCat]
40. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM.; Technology Assessment: Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer. Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models, 2007. Available at: http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=52. Accessed on November 11, 2014.
41. Siegel JE, Weinstein MC, Russell LB, Gold MR.; Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 1339-1341.
42. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB.; Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 1253-1258.
43. Lipscomb J, Weinstein MC, Torrance GW.; Time preference. In:, Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996: 214-235.
44. Briggs AH, Sculpher M, Claxton K.; Making decision models probabilistic. In:, Briggs AH, ed. Decision Modelling for Health Economic Evaluation. Cambridge, MA: Oxford University Press; 2006: 77-120.
45. Sharaf RN, Myer P, Stave CD, Diamond LC, Ladabaum U.; Uptake of genetic testing by relatives of Lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol. 2013; 11: 1093-1100.
46. Day LW, Bhuket T, Allison J.; FIT testing: an overview [serial online]. Curr Gastroenterol Rep. 2013; 15: 357.